دورية أكاديمية
أعرض في EDS

TNF blockers alone and associated with Benznidazole impact in vitro cytokine dynamics in chronic Chagas disease.

التفاصيل البيبلوغرافية
العنوان: TNF blockers alone and associated with Benznidazole impact in vitro cytokine dynamics in chronic Chagas disease.
المؤلفون: Torres DJL; Universidade Federal de Pernambuco-UFPE, Recife, Pernambuco, Brazil.; Instituto Aggeu Magalhães-IAM/Fiocruz, Recife, Pernambuco, Brazil., Dos Santos Oliveira KK; Universidade Federal de Pernambuco-UFPE, Recife, Pernambuco, Brazil.; Instituto Aggeu Magalhães-IAM/Fiocruz, Recife, Pernambuco, Brazil., da Silva Barros M; Universidade Federal de Pernambuco-UFPE, Recife, Pernambuco, Brazil.; Instituto Aggeu Magalhães-IAM/Fiocruz, Recife, Pernambuco, Brazil., Moreira LR; Universidade Federal de Pernambuco-UFPE, Recife, Pernambuco, Brazil.; Instituto Aggeu Magalhães-IAM/Fiocruz, Recife, Pernambuco, Brazil., de Freitas Firmino L; Universidade Federal de Pernambuco-UFPE, Recife, Pernambuco, Brazil.; Instituto Aggeu Magalhães-IAM/Fiocruz, Recife, Pernambuco, Brazil., da Piedade Costa Reis de Albuquerque M; Ambulatório De Doença De Chagas e Insuficiência Cardíaca do Pronto Socorro Cardiológico De Pernambuco, Recife, Pernambuco, Brazil., da Glória Aureliano Melo Cavalcante M; Ambulatório De Doença De Chagas e Insuficiência Cardíaca do Pronto Socorro Cardiológico De Pernambuco, Recife, Pernambuco, Brazil., Martins SM; Ambulatório De Doença De Chagas e Insuficiência Cardíaca do Pronto Socorro Cardiológico De Pernambuco, Recife, Pernambuco, Brazil., de Oliveira Junior WA; Ambulatório De Doença De Chagas e Insuficiência Cardíaca do Pronto Socorro Cardiológico De Pernambuco, Recife, Pernambuco, Brazil., da Silva Rabello MC; Instituto Aggeu Magalhães-IAM/Fiocruz, Recife, Pernambuco, Brazil., de Lorena VMB; Instituto Aggeu Magalhães-IAM/Fiocruz, Recife, Pernambuco, Brazil.
المصدر: Parasite immunology [Parasite Immunol] 2024 Feb; Vol. 46 (2), pp. e13024.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley Country of Publication: England NLM ID: 7910948 Publication Model: Print Cited Medium: Internet ISSN: 1365-3024 (Electronic) Linking ISSN: 01419838 NLM ISO Abbreviation: Parasite Immunol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Oxford, Wiley
مواضيع طبية MeSH: Chagas Disease*/drug therapy , Heart Diseases*/drug therapy , Heart Diseases*/parasitology , Nitroimidazoles*, Humans ; Cytokines ; Interferon-gamma ; Interleukin-2 ; Interleukin-4 ; Leukocytes, Mononuclear ; Tumor Necrosis Factor Inhibitors/therapeutic use ; Tumor Necrosis Factor-alpha
مستخلص: Studies involving the immune response in Chagas disease suggest an imbalance in the immune response of symptomatic patients, with an inflammatory profile dominating in Chagas heart disease, mainly by tumour necrosis factor (TNF). TNF is considered a key cytokine in immunopathology in chronic carriers in several processes during the immune response. Our work aimed to evaluate regulatory (interleukin [IL]-4 and IL-10) and inflammatory (TNF, interferon-gamma [IFN-γ], IL-2 and IL-6) cytokines in peripheral blood mononuclear cells culture supernatants. of affected patients with undetermined clinical forms-IND (n = 13) mild heart form-CARD1 (n = 13) and severe cardiac form-CARD2 (n = 16), treated in vitro with two TNF blockers, Adalimumab (ADA) and Etanercept (ETA) alone or in association with Benznidazole (BZ). The results indicate that ADA was more competent in blocking TNF (compared to ETA) in all groups but with much lower levels in the CARD2 group. ETA statistically decreased TNF levels only in the CARD2 group. IFN-γ increased in the CARD2 group after treatment with ETA relative to ADA. IL-4 had its levels decreased when treated by both drugs. IL-2 was detected in cells from CARD2 carriers compared to the NEG group after treatment with both drugs. The association with BZ decreased levels of IL-2/TNF and increased IL-4. These data reinforce the participation of TNF in severe Chagas heart disease and bring perspectives on using these blockers in the immunological treatment of Chagas disease since the use of BZ is extremely limited in these patients.
(© 2024 John Wiley & Sons Ltd.)
References: Pérez-Molina JA, Molina I. Chagas disease. Lancet Lond Engl. 2018;391(10115):82-94.
WHO. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol Rec. 2015;90(6):33-43.
Nunes MCP, Beaton A, Acquatella H, et al. Chagas cardiomyopathy: an update of current clinical knowledge and management: A scientific statement from the American Heart Association. Circulation. 2018;138(12):e169-e209. doi:10.1161/CIR.0000000000000599.
Echavarría NG, Echeverría LE, Stewart M, Gallego C, Saldarriaga C. Chagas disease: chronic Chagas cardiomyopathy. Curr Probl Cardiol. 2021;46:100507.
BRASIL. Ministério da Saúde. Boletim Epidemiológico da Secretaria de Vigilância em Saúde. Doença de Chagas. Ministério da Saúde; 2021:1-38.
Dias JCP Jr, Ramos AN, Gontijo ED, et al. 2nd Brazilian consensus on Chagas disease, 2015. Rev Soc Bras Med Trop. 2016;49(Suppl 1):S3-S60. doi:10.1590/0037-8682-0505-2016.
Magalhães LMD, Gollob KJ, Zingales B, et al. Pathogen diversity, immunity, and the fate of infections: lessons learned from Trypanosoma cruzi human-host interactions. Lancet Microbe. 2022;3(9):e711-e722. doi:10.1016/S2666-5247(21)00265-2.
Montalvo-Ocotoxtle IG, Rojas-Velasco G, Rodríguez-Morales O, et al. Chagas heart disease: beyond a single complication, from asymptomatic disease to heart failure. J Clin Med. 2022;11(24):7262. doi:10.3390/jcm11247262.
Dutra WO, Menezes CAS, Villani FNA, et al. Cellular and genetic mechanisms involved in the generation of protective and pathogenic immune responses in human Chagas disease. Mem Inst Oswaldo Cruz. 2009;104(1):208-218.
Acevedo GR, Girard MC, Gómez KA. The unsolved jigsaw puzzle of the immune response in Chagas disease. Front Immunol. 2018;9:1929.
Rodrigues MM, Ribeirão M, Pereira-Chioccola V, et al. Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with aDNA vaccine containing a Trypanosoma cruzi gene. Infect Immun. 1999;67:3855-3863.
Kumar S, Tarleton RL. Antigen-specific Th1 but not Th2 cells provide protection from lethal Trypanosoma cruzi infection in mice. J Immunol. 2001;166:4596-4603. doi:10.4049/jimmunol.166.7.4596185.
Hoft DF, Eickhoff CS. Type 1 immunity provides both optimal mucosalandsystemic protection against a mucosally invasive, intracellular pathogen. Infect Immun. 2005;73(8):4934-4940. doi:10.1128/IAI.73.8.4934-4940.2005.
Koh CC, Neves EGA, Souza-Silva TG, et al. Cytokine networks as targets for preventing and controlling Chagas heart disease. Pathogens. 2023;12:171. doi:10.3390/pathogens12020171.
Gomes JAS, Bahia-Oliveira LMG, Rocha MOC, et al. Evidence that development of severe cardiomyopathy in human Chagas' disease is due to a Th1- specific immune response. Infect Immun. 2003;71:1185-1193.
Keating SM, Deng X, Fernandes F, et al. Inflammatory and cardiac biomarkers are differentially expressed in clinical stages of Chagas disease. Int J Cardiol. 2015;199:451-459. doi:10.1016/j.ijcard.2015.07.040.
Souza GR, Gomes JAS, Fares RCG, et al. Plasma cytokine expression is associated with cardiac morbidity in Chagas disease. PLoS One. 2014;9(3):e87082. doi:10.1371/journal.pone.0087082.
Almeida MS, Lorena VMB, Medeiros CA, et al. Alternative Th17 and CD4+ CD25+ FoxP3+ cell frequencies increase and correlate with worse cardiac function in Chagas cardiomyopathy. Scand J Immunol. 2018;87(4):e12650. doi:10.1111/sji.12650.
Rodrigues DBR, dos Reis MA, Romano A, et al. In situ expression of regulatory cytokines by heart inflammatory cells in Chagas' disease patients with heart failure. Clin Dev Immunol. 2012;2012:361730. doi:10.1155/2012/361730.
Torres DJL, Arruda TR, Barros MS, et al. Is a negative correlation between sTNFR1 and TNF in patients with chronic Chagas disease the key to clinical progression? Immunobiology. 2022;227(1):152166. doi:10.1016/j.imbio.2021.152166.
Silva WT, Costa HS, Lima VP, et al. Plasma levels of soluble TNF receptors are associated with cardiac function in patients with Chagas heart disease. Int J Cardiol. 2020;316:101-103. doi:10.1016/j.ijcard.2020.04.053.
Albareda MC, Olivera GC, Laucella SA, et al. Chronic human infection with Trypanosoma cruzi drives CD4+T cells to immune senescence. J Immunol. 2009;183(6):4103-4108. doi:10.4049/jimmunol.0900852.
Bestetti RB, Dellalibera-Joviliano R, Lopes GS, et al. Determination of the Th1, Th2, Th17, and Treg cytokine profile in patients with chronic Chagas heart disease and systemic arterial hypertension. Heart Vessels. 2019;34:123-133. doi:10.1007/s00380-018-1228-z.
Loo GV, Bertrand MJM. Death by TNF: a road to inflammation. Nat Rev Immunol. 2023;23(5):289-303. doi:10.1038/s41577-022-00792-3.
Iwaszko M, Biały S, Bogunia-Kubik K. Significance of interleukin (IL)-4 and IL-13 in inflammatory arthritis. Cell. 2021;10(11):3000. doi:10.3390/cells10113000.
Soares MBP, Silva-Mota KN, Lima RS, Bellintani MC, Pontes-de-Carvalho L, Ribeiro-dos-Santos R. Modulation of chagasic cardiomyopathy by interleukin-4: dissociation between inflammation and tissue parasitism. Am J Pathol. 2001;159:703-709. doi:10.1016/S0002-9440(10)61741-5.
Lorena VMB, Lorena IMB, Braz SCM, et al. Cytokine levels in serious cardiopathy of Chagas disease after in vitro stimulation with recombinant antigens from Trypanosoma cruzi. Scand J Immunol. 2010;72(6):529-539. doi:10.1111/j.1365-3083.2010.02462.x.
Bosch-Nicolau P, Ubals M, Salvador F, et al. Leishmaniasis and tumor necrosis factor alpha antagonists in the Mediterranean basin. A switch in clinical expression. PLoS Negl Trop Dis. 2019;13(8):e0007708. doi:10.1371/journal.pntd.0007708.
Navarrete-Dechent C, Majerson D, Torres M, et al. Use of tumor necrosis factor alpha (TNF α) antagonists in a patient with psoriasis and Chagas disease. An Bras Dermatol. 2015;90(3 Suppl 1):171-174. doi:10.1590/abd1806-4841.20153538.
Gibellini L, De Biasi S, Bianchini E, et al. Anti-TNF-α drugs differently affect the TNFα-sTNFR system and monocyte subsets in patients with psoriasis. PLoS One. 2016;11(12):e0167757. doi:10.1371/journal.pone.0167757.
Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug ad-herence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab. Results from eight years of surveillance of clin-ical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62:22-32. doi:10.1002/art.27227.
Hu X, Li B, Li X, et al. Transmembrane TNF-α promotes suppressive activities of myeloid-derived suppressor cells via TNFR2. J Immunol. 2014;192(3):1320-1331. doi:10.4049/jimmunol.1203195.
Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25(6):1700-1721. doi:10.1016/s0149-2918(03)80164-9.
Santora LC, Kaymakcalan Z, Sakorafas P, Krull IS, Grant K. Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cátion exchange, size exclusion chromatography, and BIAcore. Anal Biochem. 2001;299:119-129.
Liao W, Lin JX, Leonard WJ. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol. 2011;23(5):598-604. doi:10.1016/j.coi.2011.08.003.
Wallis RS. Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma. J Investig Dermatol Symp Proc. 2007;12(1):16-21. doi:10.1038/sj.jidsymp.5650031.
Bilate AMB, Salemi VM, Ramires FJ, et al. TNF blockade aggravates experimental chronic Chagas disease cardiomyopathy. Microbes Infect. 2007;9(9):1104-1113. doi:10.1016/j.micinf.2007.05.014.
Pérez AR, Bottasso O, Savino W. The impact of infectious diseases upon neuroendocrine circuits. Neuroimmunomodulation. 2009;16:96-105. doi:10.1159/000180264.
Pereira IR, Vilar-Pereira G, Silva AA, et al. Tumor necrosis factor is a therapeutic target for immunological unbalance and cardiac abnormalities in chronic experimental Chagas' heart disease. Mediators Inflamm. 2014;2014:798078. doi:10.1155/2014/798078.
Venetsanopoulou AI, Alamanos Y, Voulgari PV, et al. Epidemiology of rheumatoid arthritis: genetic and environmental influences. Expert Ver Clin Immunol. 2022;18(9):923-931. doi:10.1080/1744666X.2022.2106970.
Finckh A, Gilbert B, Hodkinson B, et al. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol. 2022;18:591-602. doi:10.1038/s41584-022-00827-y.
Pérez-Molina JA, Crespillo-Andújar C, Bosch-Nicolau P, Molina I. Trypanocidal treatment of Chagas disease Tratamiento tripanocida de la enfermedad de Chagas. Enferm Infecc Microbiol Clin (Engl Ed). 2021;39(9):458-470. doi:10.1016/j.eimce.2020.04.012.
Ciapponi A, Barreira F, Perelli L, et al. Direct evidence gap on fixed versus adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: systematic review and individual patient data meta-analysis. Trop Med Int Health. 2023;28(1):2-16. doi:10.1111/tmi.13831.
Moreira LR, Dos Santos KK, Torres DJL, et al. Benzonidazole treatment has a beneficial effect on cells infected with the Colombian strain of Trypanosoma cruzi [published online ahead of print, 2023 Apr 17]. Parasite Immunol. 2023;45:e12983. doi:10.1111/pim.12983.
Pandey RP, Nascimento MS, Franco CH, et al. Drug repurposing in Chagas disease: chloroquine potentiates Benznidazole activity against Trypanosoma cruzi in vitro and in vivo. Antimicrob Agents Chemother. 2022;66(11):e0028422. doi:10.1128/aac.00284-22.
Soares AKA, Neves PAF, Nascimento AV, et al. Benznidazole: hero or villain of cellular immune response in chronic Chagas disease patients? Immunobiology. 2021;226(1):152046. doi:10.1016/j.imbio.2020.152046.
Cevey AG, Mirkin GA, Penas FN, Goren NB. Low dose benznidazole treatment results in parasite clearance and attenuates heart inflammatory reaction in an experimental model of infection with a highly virulent Trypanosoma cruzi strain. Int J Parasitol Drugs Drug Resist. 2016;6(1):12-22. doi:10.1016/j.ijpddr.2015.12.001.
Vitelli-Avelar DM, Sathler-Avelar R, Teixeira-Carvalho A, et al. Strategy to assess the overall cytokine profile of circulating leukocytes and its association with distinct clinical forms of human Chagas disease. Scand J Immunol. 2008;68:516-525. doi:10.1111/j.1365-3083.2008.02167.x.
Campi-Azevedo AC, Gomes JAS, Teixeira-Carvalho A, et al. Etiological treatment of Chagas disease patients with benznidazole lead to a sustained pro-inflammatory profile counterbalanced by modulatory events. Immunobiology. 2015;220(5):564-574. doi:10.1016/j.imbio.2014.12.006.
Sathler-Avelar R, Vitelli-Avelar DM, Massara RL, et al. Benznidazole treatment during early-indeterminate Chagas' disease shifted the cytokine expression by innate and adaptive immunity cells toward a type 1-modulated immune profile. Scand J Immunol. 2006;64(5):554-563. doi:10.1111/j.1365-3083.2006.01843.x.
Sathler-Avelar R, Vitelli-Avelar DM, Massara RM, et al. Etiological treatment during early chronic indeterminate Chagas disease incites an activated status on innate and adaptive immunity associated with a type 1-modulated cytokine pattern. Microbes Infect. 2008;10:103-113.
Laucella SA, Mazliah DP, Bertocchi G, et al. Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clin Infect Dis. 2009;49(11):1675-1684. doi:10.1086/648072.
Cardoso CS, Ribeiro ALP, Oliveira CDL, et al. Beneficial effects of benznidazole in Chagas disease: NIH SaMi-trop cohort study. PLoS Negl Trop Dis. 2018;12(11):e0006814. doi:10.1371/journal.pntd.0006814.
Galván IL, Alonso-Padilla J, Cortés-Serra N, et al. Benznidazole for the treatment of Chagas disease. Expert Rev Anti Infect Ther. 2021;19(5):547-556. doi:10.1080/14787210.2021.1834849.
معلومات مُعتمدة: Coordination for the Improvement of Higher Education Personnel (CAPES); 474926/212-5-Universal National Council for Scientific and Technological Development (CNPq); IAM-005-Fio-22-2-50 (PROEP/Fiocruz)
فهرسة مساهمة: Keywords: Benznidazole; Chagas cardiomyopathy; cytokines; leukocytes; mononuclear; tumour necrosis factor inhibitors; tumour necrosis factor-alpha
المشرفين على المادة: YC42NRJ1ZD (benzonidazole)
0 (Cytokines)
82115-62-6 (Interferon-gamma)
0 (Interleukin-2)
207137-56-2 (Interleukin-4)
0 (Nitroimidazoles)
0 (Tumor Necrosis Factor Inhibitors)
0 (Tumor Necrosis Factor-alpha)
تواريخ الأحداث: Date Created: 20240222 Date Completed: 20240223 Latest Revision: 20240305
رمز التحديث: 20240305
DOI: 10.1111/pim.13024
PMID: 38385576
قاعدة البيانات: MEDLINE
الوصف
تدمد:1365-3024
DOI:10.1111/pim.13024